Fujirebio and Sysmex Extend Collaboration to Neurodegenerative Diseases in Immunoassay Partnership
Monday, December 04, 2023
Fujirebio Holdings and Sysmex Corporation have broadened their partnership agreement to include neurodegenerative diseases in their joint venture for contract development and manufacturing (CDMO) of the Sysmex HISCL™ series automated immunoassay systems. While Fujirebio has been providing reagents for the HISCL™ series since 2020, both companies decided in October 2023 to strengthen their collaboration.
They aim to combine their expertise in immunoassays to accelerate global expansion and advancements in these diagnostic tests. As part of this expansion, Fujirebio will develop reagents for Sysmex's HISCL™ series to sample cerebrospinal fluid (CSF) and blood in neurodegenerative diseases like Alzheimer's.
This collaboration seeks to enhance Sysmex's analytical capabilities in disease diagnosis, fostering further growth in immunoassay applications. Fujirebio and Sysmex are committed to expediting the development and launch of these new tests.